Wednesday, July 14, 2021

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient

A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

from Top Health News -- ScienceDaily https://ift.tt/3xJJDMS
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Hidden blood molecules show surprising anti-aging power

Scientists have identified new anti-aging compounds produced by a little-studied blood bacterium. These indole metabolites were able to redu...